Ea. Bronsky et al., Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices, PEDIATRICS, 104(3), 1999, pp. 501-506
Background. A powder formulation of salmeterol has been shown to prevent ex
ercise-induced bronchospasm (EIB) in asthmatic children and adults; however
, the delivery device (Diskhaler; Glaxo Wellcome Inc, Research Triangle Par
k, NC) must be reloaded after 4 doses. A new multidose powder inhaler (Disk
us) provides 60 doses of salmeterol in a blister pack presentation with a d
ose counter.
Objective. To evaluate the safety and efficacy of 50-mu g salmeterol powder
via two different delivery systems (Diskhaler and Diskus) in preventing EI
B in asthmatic children.
Study Design. A randomized, double-blind, double-dummy, single-dose, placeb
o-controlled, three-way crossover study was conducted in 24 children 4 to 1
1 years of age demonstrating EIB and mild to moderate asthma. Serial forced
expiratory volume in 1 second (FEV1) was measured before and after treadmi
ll exercise challenges conducted at 1, 6, and 12 hours after study drug adm
inistration. Adverse events were also assessed.
Results. During all exercise challenges, EIB-mediated reductions in FEV1 we
re minimized or prevented in patients receiving single doses of salmeterol
powder compared with placebo. Single doses of salmeterol powder delivered v
ia either system were equally effective in preventing EIB. There were no dr
ug-related adverse events, cardiovascular, or other clinically relevant saf
ety concerns.
Conclusions. Single doses of salmeterol powder delivered by either delivery
system are safe and effective in preventing EIB for greater than or equal
to 12 hours in asthmatic children.